【摘要】 目的:探讨维生素K2对乙型肝炎病毒相关性肝细胞癌术后复发的作用。方法:肝细胞癌术后患者(54例)随机分为维生素K2组(28例。常规治疗外,口服维生素K2 45 mg,每日1次)和对照组(26例。常规治疗)。随访4年进行肝细胞癌复发和生存率分析。结果:维生素K2组12、24、36和48个月肝细胞癌累计复发率分别为14.3%、32.1%、57.1%和67.9%;对照组23.1%、57.6%、76.9%和92.3%(P<0.005)。维生素K2组第12、24、36和48个月累计生存率分别为100.0%、92.9%、85.7%和75.0%,对照组100.0%、88.5%、73.1%和65.4%。随访第4年结束时两组共16例死亡。结论:维生素K2降低了乙型肝炎病毒相关性肝细胞癌术后的复发率。更多还原

【Abstract】 Objective:To investigate the effect of Vitamin K2 on the recurrence of hepatitis B virusassociated hepatocellular carcinoma. Methods:Fifty-four patients received surgical resection were assigned randomly Vitamin K2 group(28 cases. 45 mg/d oral Vitamin K2,once a day)and control group(26 cases. conventional treatment). The recurrence and survival rates were analyzed in patients for 4 years. Results:The cumulative recurrence rates in the vitamin K2 group were 14.3%、32.1%、57.1% and 67.9%,and 23.1%、57.6%、76.9% and 92.3% in the control group at 12,24,36 and 48 months(P<0.005). The cumulative survival rates in the vitamin K2 group were 100.0%、92.9%、85.7% and 75.0%,100.0%、88.5%、73.1% and 65.4% in the control group at 12,24,36 and 48 months. Conclusion:Vitamin K2 may decrease the recurrence of hepatitis B virus-associated hepatocellular carcinoma.更多还原